Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMPO-LT: TLI and ATG for Immune Tolerance in Liver Transplantation
NCT07634562Phase 2Recruiting
- Sponsor
- Stanford University
- Start
- Sep 2026
- Primary completion
- Aug 2031
- Countries
- 1
01
Overview
Phase 2, open-label trial of antithymocyte globulin rabbit in liver failure (2 arms), sponsored by Stanford University. Primary endpoint: Success rate of immunosuppression withdrawal at 36 months. Started Sep 2026; status: recruiting.
02
Drugs
antithymocyte globulin rabbit
03
Conditions
liver failure
Beyond the preview
Go deeper on NCT07634562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07634562.